Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.

Kantarjian, Hagop M

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. [electronic resource] - Cancer Jul 2013 - 2611-9 p. digital

Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural

1097-0142

10.1002/cncr.28113 doi


Aged
Aged, 80 and over
Antimetabolites, Antineoplastic--therapeutic use
Antineoplastic Agents--administration & dosage
Aurora Kinase B
Aurora Kinases
Cytarabine--administration & dosage
Drug Administration Schedule
Female
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute--drug therapy
Male
Neutropenia--chemically induced
Organophosphates--administration & dosage
Protein Serine-Threonine Kinases--antagonists & inhibitors
Quinazolines--administration & dosage
Stomatitis--chemically induced
Treatment Outcome